Katy Knight

Recent Mergers and Acquisitions

• Oxford Immunotec, a NASDAQ-listed UK plc, on its $591 million sale to PerkinElmer by UK scheme of arrangement.
• Ergomed PLC on its acquisition of ADAMAS Consulting Group Limited, a leading global regulatory compliance provider.
• Acted for Sensata Technologies on its acquisition of Cynergy3, a UK-headquartered global manufacturer of liquid level and flow sensors, pressure transducers, and radio frequency relays.

Recent Fundraisings and Investments

• Oxford Science Enterprises on various investments, including its seed investment in University of Oxford spin-out Alethiomics.
• Sofinnova Partners as lead investor on the $40 million financing round of Sphere Fluidics.
• Alchemab Therapeutics on its £60 million ($82 million) series A financing.
• Venture capital firm ATP (Apple Tree Partners) on the formation of Adendra Therapeutics Ltd., a spin-out from the Francis Crick Institute in London that will discover and develop treatments for cancers and autoimmune diseases by applying new insights into regulation of adaptive immune responses by dendritic cells.
• Novo Ventures, Cowen Healthcare Ventures, F-Prime and Sanofi as a syndicate on their £44.5 million Series B financing of NodThera Limited.
• BenevolentAI, a global leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, on its $80 million equity investment round by new and existing investors.
• Salesforce Ventures on:
  • its Series B and Series C investments in AI identity verification company Onfido;
  • its Series A investment in Hopin; and
  • its Series A investment in Crehana Education.

Other Recent Transactional Work

• Reliance Strategic Business Ventures, a unit of Reliance Industries, on its $220 million investment in Sanmina's India unit to establish a joint venture with Sanmina to build an electronics manufacturing hub in India.
• Merck & Co., Inc. on its global reorganisation in connection with the spin-off of its women’s health, trusted legacy brands and biosimilars businesses.